ArticleCureus2026
Characteristics of Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer Eligible for Adjuvant Cyclin-Dependent Kinase 4/6 (CDK4/6) Inhibitors: Real-Life Evidence in a Colombian Cancer Center.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background The introduction of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in the adjuvant setting for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (BC) has expanded treatment options for high-risk patients. However, real-world data on eligibility for these therapies in Latin American populations remain limited. Methods This retrospective study analyzed 334 patients with HR+/HER2- early breast cancer (stages I-III) treated at a Colombian cancer center (2022-2024). Eligibility criteria for adjuvant abemaciclib (monarchE) and ribociclib (NATALEE) trials were applied. Clinicopathological characteristics and treatment patterns were assessed. Results Among abemaciclib-eligible patients (36.2%, n=121), 54.5% had ≥4 positive nodes, and 45.5% met alternative high-risk criteria (1-3 nodes plus tumor size of ≥5 cm or grade 3 or Ki-67 of ≥20%). Ribociclib-eligible patients (59%, n=197) included 53.8% with stage III disease and 12.7% with node-negative, grade 3 tumors. Descriptive comparison with pivotal trials shows that compared to pivotal trials, our cohort had an older median age (61 versus 51-52 years) and a lower prevalence of grade 3 tumors (17.1% versus 30%-40%). Conclusion A substantial proportion of Colombian patients with HR+/HER2- early breast cancer qualify for adjuvant CDK4/6i, particularly those with nodal involvement. These findings highlight both the clinical opportunity and economic challenges of implementing these therapies in resource-limited settings while underscoring the need for improved early detection to reduce advanced presentations. Eligibility based on clinical-pathological criteria identifies a high-risk group, though optimal selection may require biomarker refinement where available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.